Are You Leveraging the Drug Discovery and Early Development Outsourcing Services Ecosystem to Accelerate Growth?
Frost & Sullivan
MARCH 22, 2024
However, the pharma/biopharma industry shows overall stagnant R&D activity. Small-to-mid and emerging biopharma players contribute over 16%. Techniques like next generation sequencing (NGS) and high throughput screening (HTS) leading to increased collaboration between CROs and diagnostics players and central labs.
Let's personalize your content